BIP-135

Research use only, not for human use.

BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.

BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.(In Vitro):BIP-135 (20 μM; 48 hours) is a superior neuroprotective agent in the model of oxidative stress. BIP-135 (20-30 μM; 72 hours) increases the survival motor neuron (SMN) protein levels at a dose of 25 μM in human SMA fibroblasts. And the typical bell-shaped dose-response curve is observed due to some toxicity at higher concentrations.(In Vivo):BIP-135 (75 mg/kg; i.p.; daily; from postnatal day 0 to 21) prolongs the median survival time of Δ7 SMA KO mouse model of spinal muscular atrophy. And it does not appear to be toxic and was well-tolerated by the animals (no decrease in body weight).

BIP-135 (20-30 μM; 72 hours) increases the survival motor neuron (SMN) protein levels at a dose of 25 μM in human SMA fibroblasts. And the typical bell-shaped dose-response curve is observed due to some toxicity at higher concentrations.BIP-135 (20 μM; 48 hours) is a superior neuroprotective agent in the model of oxidative stress. Western Blot Analysis Cell Line:Human SMA fibroblasts Concentration:20 μM, 25 μM, 30 μM Incubation Time:72 hours Result:Led to a 7-fold increase in SMN levels at 25 μM.

BIP-135 does not appear to be toxic and was well-tolerated by the animals (no decrease in body weight).BIP-135 (75 mg/kg; i.p.; daily; from postnatal day 0 to 21) prolongs the median survival time of Δ7 SMA KO mouse model of spinal muscular atrophy. Animal Model:Male and female SMN2+/+, SMN2Δ7+/+, Smn+/– mice Dosage:75 mg/kg Administration:Intraperitoneal injection; daily; from postnatal day 0 to 21Result:Caused a modest extension in the median survival of SMA KO animals by two days.

——

PI3K/Akt/mTOR signaling

GSK-3

——

——

——

941575-71-9

421.25

C21H13BrN2O3

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (148.37 mM)

Cn1cc(C2=C(C(=O)NC2=O)c2coc3ccccc23)c2cc(Br)ccc12

——

(-20℃)

With Ice Pack

≥ 2 years